

Effective Date: 8/2018
Revised: 11/2019
Reviewed: 8/2018, 11/2019, 7/2020, 5/2021, 4/2022, 01/2023, 01/2024, 01/2025, 01/2026
Scope: Medicaid

Step Therapy Exception Criteria

POLICY

I. CRITERIA FOR APPROVAL

An authorization may be granted when all the following criteria are met:

- A. The requested drug/product is being used for an FDA-approved indication or a medically accepted indication as defined in any one of the following standard reference compendia: American Hospital Formulary Service Drug information (AHFS-DI), Thomson Micromedex DrugDex, Clinical Pharmacology, Wolters Kluwer Lexi-Drugs, or peer-reviewed published medical literature indicating that sufficient evidence exists to support use.
- B. The prescribed dose and quantity fall within the FDA-approved labeling or within compendia-supported dosing guidelines.
- C. All relevant documentation (e.g., lab values, treatment plan, medical chart notes) is provided.
- D. Rationale provided for why the use of first-line agents, including the generic and biosimilar alternative, if available are not appropriate for the patient.

II. COVERAGE DURATION

- Up to 12 months as determined by FDA guidance and internal policies and procedures

III. REFERENCES

1. NHPRI Formulary Management Policy and Procedure.